본문 바로가기
KERD
논문KCI 등재

Comparison of Efficacy of Cefoperazone/Sulbactam and Imipenem/Cilastatin for Treatment of Acinetobacter Bacteremia

용동은|이경원|송영구|최준용|윤희정|신소연|김창오|박윤선|김준명|김영근|김명수|김연아
연세대학교의과대학 (Yonsei University College of Medicine)|2006.02|Yonsei Medical Journal|제47권 제1호|pp. 63-69

2

조회

0

다운로드

1

인용

0

참고문헌

주제분류의학일반

초록

Abstract

Multiple antibiotic reisistance threatens successful treatment of Acinetobacter baumannii infections worldwide. Increasing interest in the well-known activity of sulbactam against the genus Acinetobacter has been aroused. The purpose of this study was to compare the outcomes for patients with Acinetobacter bacteremia treated with cefoperazone/sulbactam versus imipenem/cilastatin. Forty-seven patients with Acinetobacter baumannii bacteremia were analyzed through a retrospective review of their medical records for antibiotic therapy and clinical outcome. Thirty-five patients were treated with cefoperazone/sulbactam, and twelve patients with imipenem/ cilastatin. The percentage of favorable response after 72 hours was not statistically different between cefoperazone/ sulbactam group and imipenem/ cilastatin group.The mortality rate was not statistically different, too. Cefoperazone/sulbactam was found to be as useful as imipenem/cilastatin for treating patients with Acinetobacter bacteremia.

참고문헌 (26)

  1. "Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumanni", 36, pp.1268~1274 (2003)
  2. "Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii", 42, pp.793~802 (1998)
  3. "Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features", 9, pp.148~165 (1996)
  4. "Bacteremia due to Acibetobacter baumannii: epidemiology, clinical findings, and prognostic features", 22, pp.1026~1032 (1996)
  5. "Increasing prevalence of vancomycin-resistant Enterococci, and cefoxitin-, imipenem-and fluoroquinolone-resistant Gram-negative bacilli: a KONSAR study in 2002", 45, pp.598~608 (2004)
  6. "Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem", 8, pp.144~153 (2002)
  7. "Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia", 34, pp.1425~1430 (2002)
  8. "Enterobacteriaceae: introduction and identification", pp.442~458 (1999), American Society for Microbiology
  9. "National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial disk susceptibility testing-twelfth informational supplement" (2002), National Committee for Clinical Laboratory Standards
  10. "CDC definitions for nosocomial infections", pp.128~40
  11. "Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis", 115(j), pp.529~535 (2003)
  12. "Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment", 8, pp.687~693 (2002)
  13. "Nishino T. In-vitro and in-vivo activities of sulbactam and YTR830H against Acinetobacter calcoaceticus. J Antimicrob Chemother 1990", pp.677~82
  14. "et al. In vitro antimicrobial production of beta- lactamases and chloramphenicol acetyltransferae by and susceptibility of clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 1993", ami(glycoside-modifying enzymes), pp.138~41
  15. "Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains", 47, pp.479~482 (2001)
  16. "Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastin or ampicillin-sulbactam", 21, pp.142~148 (2001)
  17. "et al. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis 1993", pp.448~51
  18. "In vitro activity of cefoperazone- sulbactam combination against cefoperazone resistant clinical isolates in a Malaysian general hospital", 17, pp.73~76 (1995)
  19. "In vitro antimicrobial activity of cefoperazone-sulbactam combinations against 554 clinical isolates including a review and beta-lactamase studies. Diagn Microbiol Infect Dis 1985", pp.489~99
  20. "Moellering RCJ. In vitro activity of cefoperazone-sulbactam combinations against cefoperazone-resistant clinical bacterial isolates. Eur J Clin Microbiol Infect Dis 1989", pp.624~6
  21. "Washington JA. Comparative in vitro activity of cefoperazone andvarious combinations of cefoperazone", sulbactam. Diagn Microbiol Infect Dis 1989, 45~9
  22. "Emerging importance of multidrug-resistant Acibetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiologicalfeatures, and trend in the SENTRY antimicrobial surveillance program (1997- 1999)", 32, pp.104~113 (2001)
  23. "Evaluation of the in vitro activity of sixbroad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan", 34, pp.123~134 (1999)
  24. "Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta-lactams in Colombia using the Etest method", 29, pp.265~272 (1997)
  25. "Reboli AC. Infections caused by imipenem- resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis 1993", pp.448~51
  26. "Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacterbaumannii", 28, pp.1008~1011 (1999)

관련 논문AI추천

The Efficacy of Penicillins with β-lactamase Inhibitor or Cefmetazole against Pneumonia in which ESBL-Producing Bacteria were Isolated from SputumGoto Akihiko, Hiramatsu Kazufumi, Kadota Jun-ichi, Komiya Kosaku대한감염학회 · Infection and Chemotherapy2021 · 제53권 제3호Comments on the Published Meta-Analysis of Clinical and Microbiologic Efficacy and Safety of Imipenem/Cilastatin/Relebactam in Complicated InfectionsJafarzadeh Fatemeh, Mohammadi Amirhossein, Vaziri Ali Zaman대한감염학회 · Infection and Chemotherapy2021 · 제53권 제3호Clinical and Microbiologic Efficacy and Safety of Imipenem/Cilastatin/Relebactam in Complicated Infections: A Meta-analysisAbdullah Jahangir, Ahmad Jahangir, Allison Glaser, Rachelle Hamadi, Syeda Sahra대한감염학회 · Infection and Chemotherapy2021 · 제53권 제2호Reply: Comments on the Published Meta-Analysis of Clinical and Microbiologic Efficacy and Safety of Imipenem/Cilastatin/Relebactam in Complicated InfectionsAbdullah Jahangir, Syeda Sahra대한감염학회 · Infection and Chemotherapy2021 · 제53권 제3호Reply: The Efficacy of Penicillins with β-lactamase Inhibitor or Cefmetazole against Pneumonia in which ESBL-Producing Bacteria were Isolated from SputumKang Cheol-In대한감염학회 · Infection and Chemotherapy2021 · 제53권 제3호High-dose Sulbactam Treatment for Ventilator-Associated Pneumonia Caused by Carbapenem-Resistant Acinetobacter Baumannii권선중, 정인범, Do Yeon Jo, Ji Woong Son, Moon Jun Na대한중환자의학회 · Acute and Critical Care2016 · 제31권 제4호

이 간행물의 다른 논문 (12건)

Human Papillomavirus Type 16 E5 Protein as a Therapeutic Target김상우, 양주성pp. 1-14Further Increase of Vancomycin-Resistant Enterococcus faecium, Amikacin- and Fluoroquinolone-Resistant Klebsiella pneumoniae, and Imipenem-Resistant Acinetobacter spp. in Korea정석훈, 박기형, 하경임, 정윤섭, 이경원, 용동은, 신종희, 임환섭pp. 43-54Radiologic and Clinical Features of Idiopathic Granulomatous Lobular Mastitis Mimicking Advanced Breast Cancer정우희, 김은경, 이한경, 이제희, 곽규성, 오기근pp. 78-84Quantitative EMG Changes During 12-Week DeLorme's Axiom Strength Training조상현, 이영희, 권오윤, 신화경pp. 93-104The Actual Five-year Survival Rate of Hepatocellular Carcinoma Patients after Curative Resection박준성, 최진섭, 윤동섭, 이우정, 김병로, 이재길, 강창무, 김경식pp. 105-112
원문 보기